Skip to main content
main-content

The independent medical news service

22-09-2020 | Oncology | News | Article

NSCLC CNS recurrence significantly reduced with adjuvant osimertinib

Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.

21-09-2020 | Oncology | News | Article

Postoperative RT ‘not recommended’ for resected advanced NSCLC

Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.

21-09-2020 | Oncology | News | Article

Nivolumab–cabozantinib ‘a potential first-line option’ for advanced RCC

The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.

20-09-2020 | Oncology | News | Article

Sacituzumab govitecan demonstrates ‘significant activity’ against heavily pretreated mUC

Further findings from the TROPHY-U-01 trial indicate that the Trop-2-directed antibody–drug conjugate sacituzumab govitecan has efficacy in heavily pretreated patients with metastatic urothelial cancer.

20-09-2020 | Oncology | News | Article

IMpassion130: ‘Clinically meaningful’ OS boost with atezolizumab in PD-L1-positive advanced TNBC

The final overall survival results of the IMpassion130 trial continue to support the first-line use of atezolizumab plus nab-paclitaxel in PD-L1-expressing patients with metastatic triple-negative breast cancer.

20-09-2020 | Oncology | News | Article

Consolidation nivolumab–ipilimumab fails to boost limited-stage SCLC survival after CRT

ETOP/IFCT 4-12 STIMULI findings do not support the use of consolidation nivolumab plus ipilimumab for limited-stage small-cell lung cancer patients who have completed chemoradiotherapy and prophylactic cranial irradiation.

18-09-2020 | Oncology | News | Article

FDA issues alert on atezolizumab–paclitaxel duo in breast cancer

Click through for the details of this announcement

17-09-2020 | Oncology | News | Article

ICI therapy tied to reduced second primary cancer risk

People with cancer who receive treatment with immune checkpoint inhibitors may have a reduced risk for a second primary cancer, report French researchers.

16-09-2020 | Oncology | Highlight | Article

ctDNA accurately identifies breast cancer targeted therapy candidates

Testing for circulating tumor DNA accurately identifies patients with breast cancer suitable for mutation-targeted therapies, results of the phase 2a plasmaMATCH trial show.

15-09-2020 | Oncology | News | Article

COVID-19: High mortality risk for cancer patients confirmed

A pooled analysis has confirmed the high mortality rate among adults with cancer and comorbid COVID-19.

14-09-2020 | Oncology | News | Article

Long-term recurrence rates similar with partial vs whole breast irradiation

Long-term ipsilateral breast tumor recurrence rates are similar whether women are treated with accelerated partial-breast irradiation or whole-breast irradiation, results of the phase 3 APBI-IMRT-Florence trial show.

11-09-2020 | Oncology | News | Article

FDA approves liquid biopsy test for somatic, germline mutations

Click through to read more

10-09-2020 | Oncology | News | Article

Post-radiotherapy ipilimumab shows long-term survival benefits in mCRPC

Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.

10-09-2020 | Diabetes | News | Article

New-onset type 2 diabetes accompanied by weight loss may point to pancreatic cancer risk

Type 2 diabetes and weight loss are independently associated with an increased risk for pancreatic cancer, and this risk is further elevated when weight loss occurs together with recent-onset diabetes, according to results from a cohort study.

09-09-2020 | Oncology | News | Article

UKCCMP data suggest varying COVID-19 susceptibility, severity by tumor type

In patients with cancer, the risk for and severity of COVID-19 differs by tumor type, indicates an analysis of data from the UK Coronavirus Cancer Monitoring Project.

09-09-2020 | Oncology | News | Article

Meta-analysis indicates benefit of shorter trastuzumab duration in early breast cancer

In patients with early-stage breast cancer, shorter durations of adjuvant trastuzumab therapy are noninferior to the standard 1-year schedule with regard to disease-free survival, suggests an individual patient data meta-analysis.

08-09-2020 | Rheumatology | News | Article

Cancer risk factors described for patients with SLE

Among patients with systemic lupus erythematosus, the risk for cancer may be increased in older patients, men, and those who smoke, suggests an analysis of data from an international cohort.

08-09-2020 | Oncology | News | Article

Multiple language versions of NCCN guidelines now available

Read more about this announcement here

07-09-2020 | Oncology | News | Article

Adolescent, young adult germ cell cancer patients show diverse range of presenting symptoms

The BRIGHTLIGHT study has found that adolescent and young adult cancer patients, including those with testicular cancer and other germ cell tumors, present with a wide range and combination of cancer symptoms.

07-09-2020 | Oncology | News | Article

AURA3 shows no OS benefit of osimertinib vs chemotherapy

The phase 3 AURA3 trial has failed to demonstrate a significant overall survival gain with second-line osimertinib versus platinum–pemetrexed in patients with advanced non-small-cell lung cancer carrying the EGFR T790M resistance mutation.

Image Credits